Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Martijn van Beers, Sarah W. Mount, Katrijn Houben, Harry R. Gosker, Lisanne Schuurman, Frits M.E. Franssen, Daisy J.A. Janssen, Annemie M.W.J. Schols. Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial. ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021

Member's Comments

No comment yet.

Related content which might interest you: Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009 PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Effectiveness of influenza vaccination in asthmatic children: randomised, double-blind, placebo-controlled trial Source: Eur Respir J 2002; 20: Suppl. 38, 146s Year: 2002 Chinese herbs in treatment of influenza: A multi-centre, randomized, double-blind, placebo-controlled trial Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010 Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Randomized double-blind placebo-controlled trial of azithromycin in lung transplantation: first results Source: Annual Congress 2008 - New insights and treatment options for bronchiolitis obliterans syndrome after lung transplantation Year: 2008 Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 The early use of Antibiotics for at Risk CHildren with InfluEnza-like illness (ARCHIE): a double-blind randomised placebo-controlled trial Source: Eur Respir J, 58 (4) 2002819; 10.1183/13993003.02819-2020 Year: 2021 The effect of bronchodilators in the exercise capacity and thoracoabdominal mechanics of subjects with bronchiectasis: a randomized crossover, double-blinded, placebo-controlled trial Source: Virtual Congress 2020 – Exercise tolerance and functional status across respiratory diseases Year: 2020 Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022 Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 A randomized double-blind placebo-controlled trial on the short and long-term effects of electro acupuncture on moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 502s Year: 2006 Efficacy and costs of telehealth for the management of COPD: PROMETE II, a multicentre, randomized controlled trial Source: International Congress 2017 – New trends in pulmonary rehabilitation and chronic care Year: 2017 Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study Source: ERJ Open Res, 7 (1) 00077-2021; 10.1183/23120541.00077-2021 Year: 2021 Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021 Umeclidinium in patients with COPD: a randomised, placebo-controlled study Source: Eur Respir J 2014; 43: 72-81 Year: 2004 Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial Source: Eur Respir J, 59 (1) 2100752; 10.1183/13993003.00752-2021 Year: 2022